Press Releases

Date Title and Summary Additional Formats
Toggle Summary Zynerba Pharmaceuticals Builds Management Team
RADNOR, PA – (PR Newswire – October 1, 2014) Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal cannabinoid treatments, today named three seasoned pharmaceutical executives to its management team.
View HTML
Toggle Summary Zynerba Pharmaceuticals Appoints New Leadership Team: Armando Anido Named Chairman and CEO, Terri Sebree Named President
RADNOR, PA – (PR Newswire – October 1, 2014) Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal cannabinoid treatments, today named two leading industry veterans with track records of success in patch and gel transdermal delivery
View HTML
Toggle Summary Zynerba Pharmaceuticals Raises $13 Million to Develop First and Only Transdermal Cannabinoid Therapies
RADNOR, PA – (PR Newswire – October 15, 2014) Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal cannabinoid treatments, today announced the successful closing of $13 million in funding.
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at Oppenheimer 25th Annual Healthcare Conference
RADNOR, PA – (PR Newswire – November 19, 2014) Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the company will present at the Oppenheimer 25th Annual Healthcare
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014
RADNOR, PA – (PR Newswire – November 26, 2014) Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the company will present at the Piper Jaffray 26th Annual Healthcare
View HTML
Toggle Summary Zynerba Pharmaceuticals Appoints Richard A. Baron VP and CFO
RADNOR, PA – (PR Newswire – January 5, 2015) Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, announced that the appointment of Richard A. Baron as vice president and chief financial officer
View HTML
Toggle Summary Zynerba Files Registration Statement for Proposed Initial Public Offering of Common Stock
Devon, PA, June 30, 2015 – Zynerba Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Pricing of Its Initial Public Offering
DEVON, Pa. , Aug. 4, 2015 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. , announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts.
View HTML
Toggle Summary Zynerba Pharmaceuticals Builds Out Board of Directors
High-Caliber Appointees Offer Track Record of Success in Building Innovative Pharmaceutical Companies as Company Closes IPO DEVON, Pa. , Aug. 6, 2015 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), announced today that it has appointed six new members of its board of directors.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Closing of Its Initial Public Offering and Exercise in Full of Option to Purchase Additional Shares
DEVON, Pa. , Aug. 10, 2015 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), announced today the closing of its initial public offering of 3,450,000 shares of common stock at a public offering price of $14.00 per share, before underwriting discounts, which includes the exercise in
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at BIO Investor Forum 2015
DEVON, Pa. , Oct. 07, 2015 (GLOBE NEWSWIRE) --   Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the company will present at the BIO Investor Forum .
View HTML
Toggle Summary Zynerba Pharmaceuticals Initiates Phase 1 Clinical Trial for ZYN002 CBD Gel
First and Only Patent-Protected Synthetic CBD Gel Being Studied in Refractory Epilepsy, Fragile X Syndrome and Osteoarthritis DEVON, Pa. , Oct. 20, 2015 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at Jefferies Autumn 2015 Global Healthcare Conference
DEVON, Pa. , Nov. 11, 2015 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the company will present at the Jefferies Autumn 2015 Global
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Third Quarter 2015 Financial Results and Operational Highlights
Successful IPO, Initiation of Phase 1 for ZYN002 CBD Gel and Leadership Team Build-Out DEVON, Pa. , Nov. 11, 2015 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid
View HTML
Toggle Summary Zynerba Pharmaceuticals Appoints Warren D. Cooper Lead Independent Director
DEVON, Pa. , Nov. 16, 2015 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the Company's Board of Directors has appointed Warren Cooper, MB,
View HTML
Toggle Summary Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
DEVON, Pa. , Nov. 24, 2015 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will participate in the following upcoming
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial
DEVON, Pa. , Jan. 06, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ: ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced positive initial safety results from its Phase 1 single rising
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X Syndrome
DEVON, Pa. , Feb. 25, 2016 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by  Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), please note that in the second paragraph of the release, the quote should end with "in the second half of this year," instead of "by the end of
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at 28th Annual ROTH Conference
DEVON, Pa., March 7, 2016 – Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will present at the 28th Annual ROTH Conference.
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results and Operational Highlights
Positive Initial Phase 1 ZYN002 Single Rising Dose Results Reported; Phase 1 Multiple Rising Dose Trial Underway FDA Grants ZYN002 Orphan-Drug Designation for Fragile X Syndrome Three ZYN002 Phase 2a Trials Planned for Initiation in Second Half 2016 DEVON, Pa.
View HTML
Toggle Summary Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid
Transdermal CBD Gel ZYN002 has the potential to avoid bioconversion to psychoactive THC by bypassing the gastrointestinal tract DEVON, Pa. , April 12, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports First Quarter 2016 Financial Results and Operational Highlights
DEVON, Pa. , May 12, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today reported financial results for the quarter ended March 31, 2016, and provided
View HTML
Toggle Summary Zynerba Pharmaceuticals to Participate in Upcoming Investor Meetings and Conferences
DEVON, Pa. , June 01, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will participate in various upcoming investor
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures
Two additional Phase 2 clinical trials are expected to begin in 2H16 in patients with Osteoarthritis and Fragile X Syndrome DEVON, Pa. , June 27, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
DEVON, Pa. , July 06, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will present at Cantor Fitzgerald’s
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Dosing of First Patients in Phase 2 STAR 1 Clinical Study of ZYN002 CBD Gel in Adult Epilepsy Patients with Refractory Focal Seizures
DEVON, Pa. , Aug. 01, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the first patients have been dosed in the
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at Canaccord Genuity’s 36th Annual Growth Conference
DEVON, Pa. , Aug. 03, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will present at Canaccord Genuity’s
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Second Quarter 2016 Financial Results and Organizational Changes
Jim Fickenscher will assume role as Chief Financial Officer, VP, Corporate Development Dr. Nancy Tich appointed VP, Clinical, in a newly created position DEVON, Pa. , Aug. 11, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company
View HTML
Toggle Summary Zynerba Pharmaceuticals Launches Phase 2 Clinical Trial of ZYN002 CBD Gel for Treatment of Osteoarthritis
DEVON, Pa. , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has initiated a Phase 2 clinical trial,
View HTML
Toggle Summary Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
DEVON, Pa. , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will present at various upcoming investor
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer
DEVON, Pa. , Sept. 13, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company’s Board of Directors granted
View HTML
Toggle Summary Zynerba Provides Clinical Update for Lead Development Candidates – ZYN001 and ZYN002
Phase 1 clinical trial for ZYN001 is expected to begin in 1H17 Topline results for three Phase 2 clinical trials for ZYN002 are on track for 1H17 DEVON, Pa. , Oct. 17, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Initiation of STAR 2 Open-Label Extension Clinical Trial for ZYN002 CBD Gel in Adult Refractory Epilepsy Patients
DEVON, Pa. , Nov. 02, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the enrollment of the first patients into the STAR 2
View HTML
Toggle Summary Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
DEVON, Pa. , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will participate at various
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Third Quarter 2016 Financial Results and Operational Highlights
DEVON, Pa. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today reported financial results for the third quarter
View HTML
Toggle Summary Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
DEVON, Pa. , Nov. 21, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that Armando Anido , Chairman and CEO, and other
View HTML
Toggle Summary Zynerba Pharmaceuticals to Highlight Data for ZYN002 CBD Gel at the 70th Annual Meeting of the American Epilepsy Society
DEVON, Pa. , Nov. 28, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that two posters relating to ZYN002, its
View HTML
Toggle Summary Zynerba Reports Positive Results for ZYN002 CBD Gel in Phase 1 Studies at 70th Annual Meeting of the American Epilepsy Society
ZYN002 CBD gel was shown to be safe and well-tolerated across range of doses tested in healthy subjects and adult epilepsy patients with focal seizures No impairment in cognitive performance or changes in psychological health were observed DEVON, Pa. , Dec.
View HTML
Toggle Summary Zynerba Pharmaceuticals to Host Clinical Research Day on December 15, 2016 to Discuss the Role of ZYN002 CBD Gel in Multiple Diseases
Speakers include world-renowned physicians Meeting to begin at 8:00 am ET ; webcast will be available DEVON, Pa. , Dec. 08, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Initiation of the FAB-C Exploratory Phase 2 Clinical Trial of ZYN002 CBD Gel in Patients with Fragile X Syndrome
DEVON, Pa. , Jan. 03, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has initiated the FAB-C (Treatment of F
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock
DEVON, Pa. , Jan. 18, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it intends to offer and sell, subject to market
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock
DEVON, Pa. , Jan. 19, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the pricing of an underwritten public offering of
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
DEVON, Pa. , Feb. 09, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the underwriters of its previously announced
View HTML
Toggle Summary Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
DEVON, Pa. , March 01, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that Armando Anido , Chairman and Chief Executive
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Completion of Enrollment for ZYN002 in Two Phase 2 Clinical Trials for Epilepsy and Osteoarthritis
Top-line data for both Phase 2 clinical trials remains on track to report in July/August 2017 DEVON, Pa. , March 13, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal
View HTML
Toggle Summary Zynerba Pharmaceuticals to Report Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 27, 2017
Conference Call and Webcast Scheduled for 8:30 AM ET DEVON, Pa. , March 13, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Operational Highlights
Conference call to be held today at 8:30 am ET DEVON, Pa. , March 27, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Highlights
DEVON, Pa. , May 09, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today reported financial results for the first quarter
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference
DEVON, Pa. , June 01, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today announced that Zynerba's Chief Financial Officer,
View HTML
Toggle Summary Zynerba Pharmaceuticals Achieves Target Enrollment in Exploratory Phase 2 Trial of ZYN002 in Fragile X Syndrome
- Top-line data from this study remains on track to report in September 2017 - DEVON, Pa. , June 08, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic
View HTML
Toggle Summary Zynerba Pharmaceuticals Initiates ZYN001 Phase 1 Clinical Program
Phase 1 results will inform potential Phase 2 studies in patients with fibromyalgia and neuropathic pain, planned to start in 2H17 Study includes single rising dose and multiple rising dose evaluations DEVON, Pa. , June 26, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc.
View HTML
Toggle Summary Zynerba Pharmaceuticals Added to the Russell 3000® Index
DEVON, Pa. , June 26, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today announced that it has been added to the Russell
View HTML
Toggle Summary Zynerba Pharmaceuticals Mourns Passing of Director Cynthia A. Rask
DEVON, Pa. , July 28, 2017 (GLOBE NEWSWIRE) -- It is with great sadness that Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) mourns the death of Director Cynthia A. Rask , M.D. “All of the Zynerba family are mourning the loss of Cynthia, our friend and Director,” said Armando Anido , Chairman and Chief
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Second Quarter 2017 Financial Results and Operational Highlights
Top-line Phase 2 results for STAR 1 trial in epilepsy and STOP trial in osteoarthritis remain on track for reporting in August 2017 DEVON, Pa. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Top-Line Results from Phase 2 STAR 1 Trial of ZYN002 in Adult Epilepsy Patients with Focal Seizures
Company to host conference call and webcast today, August 7 at 8:30am ET DEVON, Pa. , Aug. 07, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces that Results from Phase 2 STOP Trial Support Continued Development of ZYN002 in Osteoarthritis
Zynerba to host conference call and webcast today, August 14 at 8:30 am ET DEVON, Pa. , Aug. 14, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal
View HTML
Toggle Summary Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
DEVON, Pa. , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal pharmaceutically-produced cannabinoid treatments, today announced that Armando Anido ,
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome
ZYN002 successfully met the primary endpoint and showed clinically meaningful improvements Zynerba to host conference call and webcast today, September 28 at 8:30 am ET DEVON, Pa. , Sept. 28, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at Upcoming Investor Conferences
DEVON, Pa. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today announced that Armando Anido ,
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights
DEVON, Pa. , Nov. 14, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today reported financial results for
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Poster Presentation at the 2017 Annual Meeting of the American Epilepsy Society (AES)
DEVON, Pa. , Nov. 21, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today announced the acceptance and
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 Annual Meeting of the American Epilepsy Society (AES)
- Clinically Meaningful Median Reduction in Seizures Compared to Baseline of 48% to 65% Achieved with Continued ZYN002 Treatment in STAR 2 Extension Study – Median Percent Change in Seizure Rates at Week 12 (STAR 1) and Month 3 and 6 (STAR 2) - Data Help Clarify Protocol Design for Planned ZYN002
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 Annual Meeting of the American Epilepsy Society (AES)
- Clinically Meaningful Median Reduction in Seizures Compared to Baseline of 48% to 65% Achieved with Continued ZYN002 Treatment in STAR 2 Extension Study – Median Percent Change in Seizure Rates at Week 12 (STAR 1) and Month 3 and 6 (STAR 2) - Data Help Clarify Protocol Design for Planned ZYN002
View HTML
Toggle Summary Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update
 - Focusing Strategy on Rare and Near-Rare Neurological and Psychiatric Disorders - - Pediatric Neurologist Liza Squires, M.D. Joins as Chief Medical Officer - - Conference Call to be Held at 8:30 AM Tomorrow , January 4, 2018 - DEVON, Pa. , Jan. 03, 2018 (GLOBE NEWSWIRE) --   Zynerba
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Positive Meeting with U.S. Food and Drug Administration and Plans to Conduct a Single Pivotal Study of ZYN002 in Fragile X Syndrome to Support an NDA Filing
Company Expects to Initiate Pivotal Study Mid-Year 2018 and Deliver Top-line Data in 2019 DEVON, Pa. , March 05, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Operational Highlights
DEVON, Pa. , March 12, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference
DEVON, Pa. , March 14, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Poster Presentation at the 2018 Annual Meeting of the American Academy of Neurology (AAN)
DEVON, Pa. , March 22, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating Effect of Cannabidiol Gel Treatment in Reduction of Relapse in an Addiction Model
Results show effect of transdermally-delivered cannabidiol (ZYN002) in an animal model of drug relapse and extend its therapeutic potential to relapse prevention in substance use disorders DEVON, Pa. , March 26, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc.
View HTML
Toggle Summary Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE)
DEVON, Pa. , April 10, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals Appoints John P. Butler to Board of Directors
DEVON, Pa. , April 16, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018
DEVON, Pa. , April 23, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at the 2018 Annual Meeting of the American Academy of Neurology (AAN)
Continued Improvement in Seizure Control Seen in Adult Refractory Focal Seizure Patients Receiving ZYN002 through 12 Months of Open Label Exposure Median Change in Seizure Rates at Months 3, 6, 9 and 12: All ZYN002-treated patients in STAR 2 Median Change in Seizure Rates at Months 3, 6, 9 and 12:
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights
DEVON, Pa. , May 08, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
DEVON, Pa. , May 31, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Top Line Results from ZYN001 THC-Prodrug Patch Phase 1 Study
DEVON, Pa. , July 05, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced top line results from a Phase 1 clinical program studying
View HTML
Toggle Summary Zynerba Pharmaceuticals Initiates CONNECT-FX, a Pivotal Clinical Trial of ZYN002 in Fragile X Syndrome
Study will Evaluate the Efficacy and Safety of Transdermally-Delivered Cannabidiol (CBD) in Children and Adolescents with Fragile X Syndrome Top Line Results Expected in Second Half of 2019 Zynerba to host conference call and webcast today at 8:30 am DEVON, Pa.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome
- Significant Improvements in Behavioral Symptoms Observed in Patients and Sustained through 38 Weeks of Treatment with ZYN002 - - Presentation Today at the 16 th NFXF International Fragile X Conference - FAB-C Week 38 - Extension Phase Data: ADAMS Mean Percent Improvement From Baseline FAB-C Week
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock
DEVON, Pa. , July 19, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.  All of the shares to be sold in the offering will be offered by
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock
DEVON, Pa. , July 20, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) today announced the pricing of an underwritten public offering of 4,062,500 shares of its common stock at a price of $8.00 per share, for a gross deal size of $32.5 million , before deducting underwriting
View HTML
Toggle Summary Zynerba Pharmaceuticals to Host Conference Call to Provide Second Quarter 2018 Business Update
DEVON, Pa. , July 31, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, will host a conference call at 8:30 am EDT on Thursday August 2, 2018
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference
DEVON, Pa. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Financial Officer, Jim Fickenscher
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights
Zynerba to host conference call and webcast today at 8:30 am DEVON, Pa. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference
DEVON, Pa. , Aug. 31, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Cantor Global Healthcare Conference
DEVON, Pa. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the 2018 BIO Investor Forum
DEVON, Pa. , Oct. 11, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido , Zynerba’s Chief Executive Officer,
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights
DEVON, Pa. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the third quarter ended September
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference
DEVON, Pa. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002
- Patients Experienced a 77% Improvement in Aberrant Behaviors Associated with Social Avoidance Compared to Baseline after One Year of ZYN002 Treatment - FAB0C Month 12: ADAMS Percent Improvement from Baseline with ZYN002 FAB-C Month 12: ABC-CFXS Percent Improvement from Baseline with ZYN002 -
View HTML
Toggle Summary Zynerba Pharmaceuticals Provides Clinical Update and Announces Two New Clinical Indications
- Company Will Focus on Four Childhood Neuropsychiatric Disorders: FXS, DEE, Autism Spectrum Disorder and 22q11.2 Deletion Syndrome - - Cash Runway Now Extends into the Second Half of 2020 - - Conference Call to be Held Today at 8:30 am Eastern Time - DEVON, Pa. , Dec.
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference
DEVON, Pa. , Feb. 05, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals Appoints Pamela Stephenson to Board of Directors
DEVON, Pa. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the appointment of Pamela Stephenson to its Board of
View HTML
Toggle Summary Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Cannabidiol
DEVON, Pa. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S.
View HTML
Toggle Summary Zynerba Pharmaceuticals Initiates Phase 2 Trial of Zygel™ in Autism Spectrum Disorder
- Topline Data from BRIGHT Study Expected in the First Half 2020 - - Company Selects Zygel™ as Brand Name for ZYN002 CBD Transdermal Gel - DEVON, Pa. , March 07, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Operational Highlights
DEVON, Pa. , March 11, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the fourth quarter and year
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
DEVON, Pa. , April 02, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel™ for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS)
- Designation Facilitates and Expedites Development of Drugs for Patients with Serious Unmet Medical Needs - - Enrollment Progressing in Pivotal CONNECT-FX Trial of Zygel in FXS, with Data Expected in the Second Half of 2019 - DEVON, Pa. , May 06, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals,
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights
DEVON, Pa. , May 08, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the first quarter ended March 31,
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
DEVON, Pa. , May 28, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Initiation of Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome
Topline Data from the INSPIRE Trial Expected in the First Half 2020 DEVON, Pa. , May 29, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders,
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at FDA’s Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-derived Compounds
DEVON, Pa. , May 30, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Ray Mannion , Zynerba’s Vice President of
View HTML
Toggle Summary Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Cannabidiol
DEVON, Pa. , June 11, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S.
View HTML
Toggle Summary Zynerba Pharmaceuticals Added to Russell 2000® and 3000® Indexes
DEVON, Pa. , July 01, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the Company will be added as a member of the U.S.
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at Two Upcoming Conferences
DEVON, Pa. , July 31, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights
DEVON, Pa. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the second quarter ended June 30,
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Publication of Zygel™ (ZYN002) 12-week Open Label Fragile X Syndrome Data in the Journal of Neurodevelopmental Disorders
DEVON, Pa. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the publication of data from the Phase 2 FAB-C
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Poster Presentations at the 22nd Society for the Study of Behavioural Phenotypes (SSBP) Symposium
DEVON, Pa. , Aug. 29, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of two posters
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at Two Upcoming Conferences
DEVON, Pa. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Autism Spectrum Disorder, Fragile X Syndrome, and 22q11.2 Deletion Syndrome Share a Constellation of Sociobehavioral Symptoms
- Preliminary Evidence Shows that CBD May Prove to be Effective in Managing the Spectrum of Behavioral Symptoms Associated with these Conditions – - New Data Presented Today at the Society for the Study of Behavioural Phenotypes (SSBP) Research Symposium - DEVON, Pa. , Sept.
View HTML
Toggle Summary New Caregiver-Reported Data Further Validate the Use of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) Subscales to Assess Core Behavioral Symptoms of Fragile X Syndrome (FXS)
- Ninety Percent of Interviewed Caregivers Reported Social Avoidant, Irritability, and Socially Lethargic Behaviors in their Children with FXS - - New Data Presented Today at the Society for the Study of Behavioural Phenotypes (SSBP) Research Symposium - DEVON, Pa. , Sept.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Positive Top Line Data from BELIEVE 1 Open Label Phase 2 Study of Zygel™ in Developmental and Epileptic Encephalopathies (DEE)
- Study Achieves a 44% Median Seizure Reduction in Focal Impaired Awareness (Complex Partial) and Convulsive Seizures in DEE Patients by Month Two; Reductions were Sustained through Month Six of Treatment with Zygel - - At Least 42% of these Patients Experienced a ≥50% Improvement from Month Two
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
DEVON, Pa. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
DEVON, Pa. , Oct. 25, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Vice President of Communications and
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights
- Positive Topline Results from BELIEVE 1 Phase 2 Trial of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies Suggest Compelling Seizure Reductions and Excellent Tolerability - - Topline Results from Pivotal Trial in Fragile X Syndrome On Track for 1H2020 - - Phase
View HTML
Toggle Summary Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Transdermal Cannabidiol
DEVON, Pa. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Achievement of Enrollment Target in Phase 2 Trial of Zygel™ in Autism Spectrum Disorder
- Topline Results from BRIGHT Study Expected in the Second Quarter of 2020 - DEVON, Pa. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces that Enrollment is Nearing Completion in Pivotal CONNECT-FX Trial in Fragile X Syndrome
– Company Confirms Expectation of Topline Results in the Second Quarter of 2020 – DEVON, Pa. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Achievement of Patient Screening Target for Pivotal Trial of Zygel™ in Fragile X Syndrome
- Company Expects to Complete Randomization in February 2020 - - Topline Results from Pivotal CONNECT-FX Study Remain On Track for the Second Quarter of 2020 - DEVON, Pa. , Feb. 03, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Presentations at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Annual Meeting
DEVON, Pa. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of data being
View HTML
Toggle Summary Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Purified Cannabidiol
DEVON, Pa. , Feb. 25, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel™ in Fragile X Syndrome
Topline Results are expected late in the Second Quarter of 2020 DEVON, Pa. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today
View HTML
Toggle Summary Zynerba Pharmaceuticals Presents Health State Utility Index Data on Severity of Fragile X Syndrome (FXS) and Diagnostic Challenges Faced by Caregivers
- Data Presented at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Meeting - - Health State Utility Index Data Estimate the Significant Health Burden of FXS, and Suggest the Potential Benefit of Treatment with Zygel™ - - Caregiver’s Perspective on Protracted Journey to
View HTML
Toggle Summary Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial in Autism Spectrum Disorder Indicate a Moderate-to-Severe Study Population
- New Data Presented Today at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Meeting - DEVON, Pa. , March 03, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the 32nd Annual ROTH Conference
DEVON, Pa. , March 05, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Poster Presentations at the American Academy of Neurology (AAN) 2020 Annual Meeting
DEVON, Pa. , March 09, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of three
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2019 Financial Results and Operational Highlights
- Key Recent Clinical Milestones Include Completion of Enrollment in Pivotal CONNECT-FX Trial in Fragile X Syndrome and Phase 2 BRIGHT Trial in Autism Spectrum Disorder - DEVON, Pa. , March 10, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference
DEVON, Pa. , April 10, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights
Topline Results from Pivotal CONNECT-FX and Phase 2 BRIGHT Trials Expected in the Second Quarter of 2020 DEVON, Pa., May 11, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and
View HTML
Toggle Summary Zynerba Pharmaceuticals Changes Annual Meeting of Shareholders to Virtual-Only Format in Response to COVID-19 Pandemic
DEVON, Pa., May 21, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that due to public health guidance related to the
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
DEVON, Pa., May 22, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Presentation of Phase 2 BELIEVE Safety, Efficacy and Quality of Life Data in Developmental and Epileptic Encephalopathies (DEE) at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session
DEVON, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters on the safety, efficacy and quality of life
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fragile X at 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session
- Robust Response Sustained through Two Years of Treatment with Zygel™ in Patients from Phase 2 FAB-C Trial - - Top Line Results of Pivotal CONNECT-FX Trial Expected Late in the Second Quarter of 2020 - DEVON, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder
- The BRIGHT Trial Achieved Statistically Significant and Clinically Meaningful Improvements from Baseline in All Subscales of the Aberrant Behavior Checklist - - Safety Data Reinforce Excellent Tolerability Profile of Zygel - - Zynerba to host conference call and webcast today, May 27, 2020 at
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X Syndrome
- Study Did Not Achieve Statistical Significance in Primary or Key Secondary Endpoints in Full Analysis Set - - Achieved Statistical Significance on Primary Endpoint (p=0.020) in Pre-Planned Ad Hoc Analysis of Patients with Full Methylation of the FMR1 Gene Comprising 80% of the Study Population -
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present an Update on the Zygel™ Development Program at the 17th NFXF International Fragile X Conference Research Roundup
- New Data Show Statistically Significant Improvements in Caregiver Impression of Change in Fragile X Behaviors Including Social Avoidance in Patients with Fully Methylated FMR1 genes - DEVON, Pa., July 22, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc.
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Virtual 40th Annual Canaccord Genuity Growth Conference
DEVON, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
DEVON, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the second quarter ended June 30,
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
DEVON, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals Provides Update on Recent Milestones
- Meeting with the U.S. Food and Drug Administration (FDA) Planned for 4Q2020 to Discuss the Regulatory Path Forward for Zygel™ in Children and Adolescents with Fragile X Syndrome and a Fully Methylated FMR1 Gene - - Newly Issued FXS Patent Supplements Intellectual Property Protection – - FDA
View HTML
Toggle Summary Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome
DEVON, Pa., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Virtual Joint 49th Annual Child Neurology Society & 16th International Child Neurology Society Congress (CNS-ICNA) Meeting
DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today has announced the acceptance and presentation details of two
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting
DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and oral presentation details of two sets
View HTML
Toggle Summary New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with Autism Spectrum Disorder (ASD) Presented at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CN
DEVON, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster describing data from the Phase 2 BRIGHT (An
View HTML
Toggle Summary Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting
DEVON, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster describing data from the CONNECT-FX ( C linical
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights
DEVON, Pa., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the third quarter ended September
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy Society (AES)
DEVON, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today has announced the acceptance and presentation details of two
View HTML
Toggle Summary Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES)
- New Efficacy Data Describe Strong Evidence of Seizure Reduction over 12 Months of Treatment, Including a 73% Median Reduction from Baseline in Monthly Seizure Frequency at Month 12 - - Zygel™ Improves the Profound Sleep Disturbance Often Experienced by Developmental and Epileptic Encephalopathy
View HTML
Toggle Summary Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome
- Single Trial to be Conducted in Patients with Fragile X Syndrome to Confirm Positive Results Seen in the Population of Responders in the CONNECT-FX Trial - - Conference Call and Webcast Today, December 17, 2020 at 8:30 am ET - DEVON, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals,
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences
DEVON, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chief Executive Officer of Zynerba,
View HTML
Toggle Summary Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference
DEVON, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Company management will participate in the 33 rd
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
DEVON, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the fourth quarter and full year
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
DEVON, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chief Executive Officer of
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting
DEVON, Pa., April 15, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of two
View HTML
Toggle Summary Zynerba Pharmaceuticals Presents Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting
DEVON, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel™ in Fragile X Syndrome
- Confirmatory pivotal trial expected to be initiated in the third quarter of 2021 - - Zynerba to hold conference call today, May 5, 2021 at 5:30 pm ET - DEVON, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights
– RECONNECT, a confirmatory pivotal trial of Zygel™ in patients with FXS, expected to be initiated in the third quarter of 2021 – – Cash runway well into first half 2024; $93.1 million at March 31, 2021 – DEVON, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference
DEVON, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced an oral podium presentation and a poster presentation
View HTML
Toggle Summary Notice of Settlement of Derivative Actions
DEVON, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE IN RE ZYNERBA PHARMACEUTICALS, INC. DERIVATIVE LITIGATION Lead Case No. 1:20-cv-00557-CFC NOTICE TO CURRENT ZYNERBA SHAREHOLDERS OF PROPOSED SETTLEMENT AND DISMISSAL WITH PREJUDICE OF
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
DEVON, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
DEVON, Pa., May 27, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of a poster at
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder (ASD) and Related Disorders at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
DEVON, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster today from 10:00 a.m. – 11:00 a.m.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Acceptance of Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting
DEVON, Pa., June 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of a poster at
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting
–  46.4% of shares voted, quorum not established to hold annual meeting – – Meeting scheduled to reconvene June 29, 2021 at 9:00 AM EDT – – Company strongly encourages stockholders holding unvoted proxies to cast their votes – DEVON, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals ,
View HTML
Toggle Summary Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual M
DEVON, Pa., June 11, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster today at SLEEP 2021, the 35 th Annual Meeting of
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting
- 49% of shares voted, quorum not established to hold annual meeting – - Meeting scheduled to reconvene August 3, 2021 at 9:00 AM EDT – - Company strongly encourages stockholders holding unvoted proxies to cast their votes - DEVON, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals ,
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference
DEVON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference
DEVON, Pa., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Company management will participate in a fireside
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights
On track to initiate RECONNECT, a confirmatory pivotal trial of Zygel™ in patients with FXS, in the third quarter of 2021 Positive feedback from FDA clarifies potential path forward in ASD Cash runway well into the first half of 2024; $85.8 million at June 30, 2021 DEVON, Pa., Aug.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021
DEVON, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and oral presentation details of two
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
DEVON, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open
DEVON, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the publication of results from the Company’s
View HTML
Toggle Summary Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel™ in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021
DEVON, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today presented data from the Phase 2 BRIGHT trial describing
View HTML
Toggle Summary Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
Trial will evaluate the efficacy and safety of Zygel in children and adolescents with  Fragile X Syndrome Topline results expected in second half of 2023 DEVON, Pa., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
DEVON, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition
DEVON, Pa., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2021 American
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
DEVON, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2021 National
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October
DEVON, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced oral and poster presentations at the Society for
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights
– Initiated RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X Syndrome (FXS); topline results expected second-half 2023 – – Cash runway well into the first half of 2024; $75.6 million at September 30, 2021 – DEVON, Pa., Nov.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™
DEVON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the European Patent Office has issued Patent No.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 Symposium
DEVON, Pa., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced presentation details for The BRAIN Foundation
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE
– Company plans to focus development of Zygel™ in FXS, ASD and 22q – – Company plans to initiate Phase 3 trial with Zygel in ASD in the second half of 2022 – – Zynerba to hold conference call tomorrow, January 5, 2022 at 9:00 a.m. ET – DEVON, Pa., Jan.
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference
DEVON, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the SVB Leerink Global Healthcare Conference
DEVON, Pa., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer
DEVON, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the appointment of Albert P.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome
Topline data from Phase 2 INSPIRE trial expected mid-year 2022 DEVON, Pa., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syndrome
Provides 10-year market exclusivity in EU upon regulatory approval DEVON, Pa., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders,
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
– European Commission granted orphan drug designation for Zygel™ in Fragile X syndrome (FXS) – – Continued enrollment in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with FXS; topline results expected second-half 2023 – – Completed enrollment in Phase 2 trial of Zygel in
View HTML
Toggle Summary Zynerba Pharmaceuticals to Participate in the Cantor Rare Orphan Disease Summit
DEVON, Pa., March 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Stephen O’Quinn, Vice President, Medical
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
DEVON, Pa., April 05, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chief Executive Officer of
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting
DEVON, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2022 Society of
View HTML
Toggle Summary Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting
DEVON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster at the 2022 Society of Biological Psychiatry (SOBP)
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting
DEVON, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced an oral podium presentation at the International
View HTML
Toggle Summary Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting
– Data support the long-term safety and effectiveness of Zygel – – Greatest improvements seen in those with complete methylation of their FMR1 gene – DEVON, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
– Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 – – Topline results from Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q) expected mid-year 2022 – – $69.7
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
DEVON, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
DEVON, Pa., May 24, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc.  (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced an oral podium presentation and a poster presentation
View HTML
Toggle Summary Zynerba Pharmaceuticals Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting
– Poster presentation highlights design enhancements incorporated into pivotal RECONNECT trial – – Oral presentation demonstrates long-term safety and potential effectiveness of Zygel in children and adolescents with Fragile X syndrome – DEVON, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Zynerba
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome
– The INSPIRE trial achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments – – Safety data reinforce excellent tolerability profile of Zygel – – Company will focus resources on FXS and 22q development – – Cash runway extended through
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Panel Presentation and Poster Presentations at the NFXF International Fragile X Conference
DEVON, Pa., July 07, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced two poster presentations at the 18 th NFXF
View HTML
Toggle Summary Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital
DEVON, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced it has entered into an equity purchase agreement for up to $20
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference
DEVON, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 Announced positive topline results from Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q) Company focusing
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Oral Presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium
DEVON, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the acceptance of an oral presentation at The Society for the
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference
DEVON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of
View HTML
Toggle Summary Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium
INSPIRE trial in 22q achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments, with excellent tolerability profile DEVON, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc.
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference
DEVON, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of
View HTML
Toggle Summary Zynerba Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference
DEVON, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Stephen O’Quinn, Pharm.D., Vice President, Medical Affairs,
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™
DEVON, Pa., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued Patent No.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
DEVON, Pa., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of a poster at the 2022 National Organization for
View HTML
Toggle Summary Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
DEVON, Pa., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, presented a poster at the 2022 National Organization for Rare Disorders (NORD)
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome
DEVON, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued Patent No.
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 $55.9 million in cash and cash equivalents at September 30, 2022; Cash runway into first quarter 2024 DEVON, Pa., Nov.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome
DEVON, Pa., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the European Commission (EC) has granted orphan drug
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders
Study finds patients with Fragile X who have a highly methylated FMR1 gene that were treated with Zygel showed a significant reduction in behavioral symptoms compared to those treated with placebo Topline results from follow-on RECONNECT confirmatory pivotal Phase 3 trial of Zygel in patients with
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology
DEVON, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of a poster at the 61 st Annual Meeting of the
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology
Zygel™ achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment DEVON, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
RECONNECT initial screening visits are being adversely impacted by environmental factors, such as the “Tripledemic” (high rates of RSV, influenza and COVID-19); topline results now expected first half of 2024 Cash runway extended to mid-year 2024 due to prioritization of resources on the completion
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the pathogenesis of Fragile X syndrome (FXS) Cannabidiol may help restore the function of the ECS in FXS patients according to review of data Consistent with the
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference
DEVON, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
DEVON, Pa, March 07, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of
View HTML
Toggle Summary Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank
DEVON, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today issued a statement confirming that it does not hold cash deposits or
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 European Commission granted orphan drug designation for cannabidiol, the active ingredient in Zygel, in 22q11.2 deletion syndrome $50.6
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference
DEVON, Pa., April 05, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of two posters at the 55 th Gatlinburg
View HTML
Toggle Summary Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg Conference
Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 $44.4 million in cash and cash equivalents at March 31, 2023; Cash runway to mid-year 2024 Proposal for a reverse stock split is on the
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
DEVON, Pa., May 23, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced an oral podium presentation and poster presentations at the
View HTML